A P Thrift1, J Hilal, H B El-Serag. 1. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: Few studies have examined the association between metabolic syndrome and Barrett's oesophagus (BO). Whether metabolic syndrome confers a risk greater than the sum of its components is unknown. AIM: To investigate associations between metabolic syndrome, its components and BO in white males. METHODS: We conducted a case-control study among eligible symptomatic patients scheduled for elective oesophagogastroduodenoscopy and a sample of patients eligible for screening colonoscopy recruited at primary care clinics. Metabolic syndrome was defined as the presence of at least three of: high waist-to-hip ratio (WHR), hypertriglyceridaemia, low high-density lipoprotein cholesterol, hypertension or diabetes. We used multivariate logistic regression to calculate odds ratios (OR) and 95% confidence intervals (95% CI). RESULTS: There were 244 BO cases, 209 colonoscopy and 615 endoscopy controls. Comparing BO cases with all controls, metabolic syndrome was significantly associated with BO (OR = 1.59, 95% CI 1.05-2.40) and there was a dose effect with increasing number of metabolic syndrome components (Ptrend <0.001); when all five components were present, the OR was 2.61 (95% CI 1.14-5.99). We found that among the components, high WHR, hypertension and hypertriglyceridaemia were associated with increased risk of BO. When we compared cases with the control groups separately, metabolic syndrome was associated with BO for comparisons with endoscopy controls (OR = 1.67, 95% CI 1.10-2.55) but not colonoscopy controls (OR = 0.87, 95% CI 0.49-1.54). Associations with individual components also depended on the comparison group. CONCLUSIONS: Metabolic syndrome is associated with an increased risk of Barrett's oesophagus in men undergoing endoscopy. Metabolic syndrome may confer additional risk of Barrett's oesophagus separate from obesity.
BACKGROUND: Few studies have examined the association between metabolic syndrome and Barrett's oesophagus (BO). Whether metabolic syndrome confers a risk greater than the sum of its components is unknown. AIM: To investigate associations between metabolic syndrome, its components and BO in white males. METHODS: We conducted a case-control study among eligible symptomatic patients scheduled for elective oesophagogastroduodenoscopy and a sample of patients eligible for screening colonoscopy recruited at primary care clinics. Metabolic syndrome was defined as the presence of at least three of: high waist-to-hip ratio (WHR), hypertriglyceridaemia, low high-density lipoprotein cholesterol, hypertension or diabetes. We used multivariate logistic regression to calculate odds ratios (OR) and 95% confidence intervals (95% CI). RESULTS: There were 244 BO cases, 209 colonoscopy and 615 endoscopy controls. Comparing BO cases with all controls, metabolic syndrome was significantly associated with BO (OR = 1.59, 95% CI 1.05-2.40) and there was a dose effect with increasing number of metabolic syndrome components (Ptrend <0.001); when all five components were present, the OR was 2.61 (95% CI 1.14-5.99). We found that among the components, high WHR, hypertension and hypertriglyceridaemia were associated with increased risk of BO. When we compared cases with the control groups separately, metabolic syndrome was associated with BO for comparisons with endoscopy controls (OR = 1.67, 95% CI 1.10-2.55) but not colonoscopy controls (OR = 0.87, 95% CI 0.49-1.54). Associations with individual components also depended on the comparison group. CONCLUSIONS:Metabolic syndrome is associated with an increased risk of Barrett's oesophagus in men undergoing endoscopy. Metabolic syndrome may confer additional risk of Barrett's oesophagus separate from obesity.
Authors: Jennifer Drahos; Winnie Ricker; Ruth Parsons; Ruth M Pfeiffer; Joan L Warren; Michael B Cook Journal: J Clin Gastroenterol Date: 2015-04 Impact factor: 3.062
Authors: Aaron P Thrift; Nicholas J Shaheen; Marilie D Gammon; Leslie Bernstein; Brian J Reid; Lynn Onstad; Harvey A Risch; Geoffrey Liu; Nigel C Bird; Anna H Wu; Douglas A Corley; Yvonne Romero; Stephen J Chanock; Wong-Ho Chow; Alan G Casson; David M Levine; Rui Zhang; Weronica E Ek; Stuart MacGregor; Weimin Ye; Laura J Hardie; Thomas L Vaughan; David C Whiteman Journal: J Natl Cancer Inst Date: 2014-09-30 Impact factor: 13.506
Authors: F Moki; M Kusano; M Mizuide; Y Shimoyama; O Kawamura; H Takagi; T Imai; M Mori Journal: Aliment Pharmacol Ther Date: 2007-10-01 Impact factor: 8.171
Authors: Aaron P Thrift; Jennifer R Kramer; Zeeshan Qureshi; Peter A Richardson; Hashem B El-Serag Journal: Am J Gastroenterol Date: 2013-04-09 Impact factor: 10.864
Authors: Ai Kubo; Michael Blaise Cook; Nicholas J Shaheen; Thomas L Vaughan; David C Whiteman; Liam Murray; Douglas A Corley Journal: Gut Date: 2013-01-26 Impact factor: 23.059
Authors: Natasha Stephens Münch; Hsin-Yu Fang; Jonas Ingermann; H Carlo Maurer; Akanksha Anand; Victoria Kellner; Vincenz Sahm; Maria Wiethaler; Theresa Baumeister; Frederik Wein; Henrik Einwächter; Florian Bolze; Martin Klingenspor; Dirk Haller; Maria Kavanagh; Joanne Lysaght; Richard Friedman; Andrew J Dannenberg; Michael Pollak; Peter R Holt; Sureshkumar Muthupalani; James G Fox; Mark T Whary; Yoomi Lee; Tony Y Ren; Rachael Elliot; Rebecca Fitzgerald; Katja Steiger; Roland M Schmid; Timothy C Wang; Michael Quante Journal: Gastroenterology Date: 2019-04-15 Impact factor: 22.682
Authors: Jessica L Petrick; Nan Li; Lesley A Anderson; Leslie Bernstein; Douglas A Corley; Hashem B El Serag; Sheetal Hardikar; Linda M Liao; Geoffrey Liu; Liam J Murray; Joel H Rubenstein; Jennifer L Schneider; Nicholas J Shaheen; Aaron P Thrift; Piet A van den Brandt; Thomas L Vaughan; David C Whiteman; Anna H Wu; Wei K Zhao; Marilie D Gammon; Michael B Cook Journal: Cancer Date: 2019-09-06 Impact factor: 6.921